dm+d

108432009

Articles

Choosing a suitable antidepressant for people with coronary heart disease (CHD)

2 July 2021Prescribers may need to choose a safe antidepressant in people with CHD. We guide on available options. We do not cover management of complex depression.

Safety in Lactation: Antidepressants

21 October 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Monamine-oxidase inhibitors (MAOIs) Due to the…

What is serotonin syndrome and which medicines cause it?

22 May 2020This Medicines Q&A outlines the causes and symptoms of serotonin syndrome and provides examples of medicines with the potential to cause serotonin syndrome.  

What evidence is available for the use of antidepressants for the management of menopausal hot flushes?

26 November 2019This is one of two UKMi Medicines Q&As addressing the management of menopausal hot flushes (vasomotor symptoms) with non-hormonal drug therapy.

How do you switch between tricyclic, SSRI and related antidepressants?

21 October 2019This updated Medicines Q&A provides advice on the risks and suggested strategies for switching between tricyclic (TCA), selective serotonin reuptake inhibitors (SSRI) and related antidepressants.…
Search Articles

Medicine Compliance Aid Stability

genericActavis UK Ltd

Actavis UK Ltd
generic
Tablets f/c 37.5mg, 75mg, 150mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Protect from moisture. Max 7 days in MCA.
14 October 2015

Polotid XLActavis UK Ltd

Actavis UK Ltd
Polotid XL
Capsules m/r 75mg, 150mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
14 October 2015

Efexor XLPfizer Ltd

Pfizer Ltd
Efexor XL
Capsules m/r 75mg, 150mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
No special precautions for storage
No special precautions for storage
26 October 2015

Venlalic XLAshbourne

Ashbourne
Venlalic XL
Tablets m/r 37.5mg, 75mg, 150mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Protect from moisture. Max 7 days in MCA.
14 October 2015

Lactation Safety Information

TCA: imipramine/nortriptyline SSRI: paroxetine/sertraline
Moderate level of published evidence of safety in breastfeeding
Minor adverse effects reported in a small number of breastfed infants
Monitor infant for drowsiness, poor feeding, irritability/behavioural effects
16 September 2019